Meritage Portfolio Management Has $9.65 Million Holdings in Humana Inc. (NYSE:HUM)

Meritage Portfolio Management trimmed its holdings in Humana Inc. (NYSE:HUM) by 0.9% in the third quarter, Holdings Channel reports. The institutional investor owned 30,462 shares of the insurance provider’s stock after selling 290 shares during the period. Meritage Portfolio Management’s holdings in Humana were worth $9,649,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in HUM. Mendota Financial Group LLC raised its position in shares of Humana by 9.2% in the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after buying an additional 27 shares in the last quarter. Capital Advisors Ltd. LLC increased its stake in shares of Humana by 17.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after purchasing an additional 31 shares during the last quarter. CarsonAllaria Wealth Management Ltd. raised its holdings in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares in the last quarter. Harbour Investments Inc. lifted its position in shares of Humana by 10.5% during the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock worth $161,000 after buying an additional 41 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft boosted its stake in Humana by 1.0% in the second quarter. Baader Bank Aktiengesellschaft now owns 4,421 shares of the insurance provider’s stock valued at $1,649,000 after buying an additional 42 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Trading Up 0.1 %

HUM stock traded up $0.36 during mid-day trading on Friday, reaching $288.12. The company’s stock had a trading volume of 1,691,681 shares, compared to its average volume of 2,587,340. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $527.18. The business’s 50 day moving average price is $289.38 and its 200 day moving average price is $332.67. The company has a market cap of $34.69 billion, a price-to-earnings ratio of 25.52, a price-to-earnings-growth ratio of 2.28 and a beta of 0.52.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. On average, equities research analysts predict that Humana Inc. will post 15.83 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is 31.36%.

Analyst Ratings Changes

HUM has been the subject of a number of research reports. Oppenheimer dropped their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd. Leerink Partners cut shares of Humana from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Stephens reiterated an “equal weight” rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $395.00 target price on shares of Humana in a research report on Tuesday, October 1st. Finally, Leerink Partnrs cut Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.